NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions Patients, families, and ...
InvestorsHub on MSN

Quoin advances QRX003 development after positive FDA meeting on Netherton syndrome

Quoin Pharmaceuticals (NASDAQ:QNRX) said it received encouraging regulatory feedback from the U.S. Food and Drug ...
Seeking Alpha

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases ...
Seeking Alpha

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patients have received ...
Nasdaq

Quoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome

Quoin Pharmaceuticals Ltd. announced the release of a new episode in its NETHERTON NOW video series featuring Professor Jemima Mellerio, a specialist in dermatology, who discusses the challenges of ...
Business Wire

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
Business Insider

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

ASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) today highlighted the continued growth of its NETHERTON NOW ...